Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct 19;78(16):e127.
doi: 10.1016/j.jacc.2021.06.056.

Preventing Bleeding With Direct-Acting Oral Anticoagulants

Comment

Preventing Bleeding With Direct-Acting Oral Anticoagulants

Janice B Schwartz et al. J Am Coll Cardiol. .
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. Gómez-Outes A, ALcubiLLa P, CaLvo-Rojas G, et al. Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants. J Am Coll Cardiol. 2021;77(24):2987–3001. - PubMed
    1. Granger CB, Pokorney SD. Preventing and managing bleeding with anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2021;77:3002–3004. - PMC - PubMed
    1. Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2288–2295. - PubMed
    1. Shin H, Cho MC, Kim RB, et al. Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation. J Thromb Thrombolysis. 2018;45(2): 250–256. - PubMed
    1. Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014;63(20):2141–2147 - PubMed